Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita Inc. on December 6, 2004. The filing announces the entry into a Material Definitive Agreement to acquire Gambro Healthcare, Inc., a Tennessee corporation and wholly owned subsidiary of Gambro, Inc. Gambro Healthcare operates a network of dialysis clinics throughout the United States.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or existing debt levels for DaVita Inc. The primary financial figure disclosed is the transaction value:
- Total Purchase Price: $3.05 billion (subject to adjustment).
- Financing Status: The Company has received financing commitments necessary to consummate the acquisition.
Material Changes and Transaction Details
The material change reported is the execution of a Stock Purchase Agreement to purchase all issued and outstanding shares of Gambro Healthcare, Inc. Key terms include:
- Approval: The DaVita Board of Directors unanimously approved the Agreement.
- Conditions to Closing: Includes the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and the receipt of financing.
- Supply Agreement: DaVita and an affiliate of the Parent (Gambro AB) will enter into a 10-year supply agreement. This obligates DaVita to purchase a significant majority of its hemodialysis product supply and equipment requirements from the affiliate.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary regarding future earnings projections. The primary risks and contingencies identified are:
- Regulatory Approval: Closing is contingent upon antitrust clearance (Hart-Scott-Rodino Act).
- Financing: Closing is contingent upon the receipt of financing, though commitments have been secured.
- Operational Obligations: The 10-year supply agreement creates a long-term obligation to purchase a significant majority of product supply from a specific affiliate.
Investor Verification Checklist
- Verify the final purchase price after any adjustments specified in the Stock Purchase Agreement.
- Confirm the terms and interest rates of the financing commitments secured for the $3.05 billion transaction.
- Monitor the status of the Hart-Scott-Rodino Antitrust waiting period and any regulatory approvals required.
- Review the full text of the 10-year supply agreement to understand pricing mechanisms and termination clauses.
- Assess the impact of the acquisition on DaVita's capital structure and liquidity post-closing.